![](https://lama2.com/wp-content/uploads/2024/07/Nicol-Voermans-640x320.jpg)
Dr. Voermans secures funding for extension of LAMA2-CMD natural history study
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
Whilst there are currently no available treatments for LAMA2-CMD, several potential therapeutic approaches are under development and investigation. This article…
Dr Reghan Foley has recently started a new research project in collaboration with the University College Cork / Cork’s University…
Dr. Dwi Kemaladewi and her team at the University of Pittsburgh have been diligently working on the development of a…